Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial

Main Article Content

C.E.M. Griffiths
K.A. Papp
M Song
M Miller
Y You
Y-K Shen
C Han
A Blauvelt

Keywords

psoriasis, guselkumab

Abstract

Abstract not available.

References

1. Blauvelt A., et al. J Am Acad Dermatol. 2017;76(3):405-417.

2. Griffiths C.E.M., et al. J Drugs Dermatol. 2018;17(8):826-832.